News >

Role of Neoadjuvant Chemotherapy Evolving in TNBC

Danielle Bucco
Published: Monday, Dec 04, 2017

Melanie Majure, MD

Melanie Majure, MD
The use of neoadjuvant chemotherapy to treat patients with triple-negative breast cancer (TNBC) is becoming more common and being explored in clinical trials, according to Melanie Majure, MD.

on Breast Cancer, Majure, a clinical instructor, Department of Medicine, Division of Hematology/Oncology, the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, discussed the optimal role chemotherapy for patients with TNBC and the importance of achieving a pCR.

OncLive: Please provide an overview of your presentation on optimal chemotherapy use for patients with TNBC.

Majure: I had the opportunity to speak about optimal chemotherapy regimens for TNBC. I focused my talk primarily on treatment in the early-stage setting, where I believe the data are most important. If you think about chemotherapy regimens in the metastatic setting, there has not been significant data to recommend 1 chemotherapy regimen over another.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your PatientsAug 30, 20191.5
Provider and Caregiver Connection™: Addressing Patient Concerns in the Management of Premenopausal Breast CancerAug 31, 20192.0
Publication Bottom Border
Border Publication